CLDX — Celldex Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.27bn
- $1.55bn
- $1.55m
Brief: Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Celldex Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview
Brief: Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Brief: Celldex Therapeutics Announces Pricing Of Upsized $400 Mln Public Offering Of Common Stock
Brief: Celldex Therapeutics Announces Proposed Public Offering Of Common Stock
Celldex Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Celldex Therapeutics Says It Presents Positive 12 Week Results From Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria
Celldex Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Point72 Asset Management, L.P. Reports 6.6% Passive Stake In Celldex Therapeutics
U.S. STOCKS ON THE MOVE-Eli Lilly, Innovid, New York Times
U.S. STOCKS ON THE MOVE-Robinhood Markets, eBay, Fisker
Celldex Therapeutics drops after $200 mln stock offering priced
Brief: Celldex Therapeutics Announces Pricing Of Public Offering Of Common Stock
U.S. RESEARCH ROUNDUP-Appian Corp, Eversource Energy, Victoria'S Secret & Co
U.S. STOCKS ON THE MOVE-Paramount Global, Bumble, Booking Holdings
U.S. STOCKS ON THE MOVE-Constellation Energy, Bloomin' Brands, Air Lease
U.S. STOCKS ON THE MOVE-Sensei, Celldex, Bluegreen Vacations
Celldex rises on success of skin disease drug in mid-stage trial